Dung T Le

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc Cellular vaccine approaches
    Dung T Le
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Bunting Blaustein Cancer Research Building, Room 407, Baltimore, MD 21231, USA
    Cancer J 16:304-10. 2010
  2. pmc CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response
    Dung T Le
    The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Int J Cancer 129:636-47. 2011
  3. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013
  4. ncbi request reprint Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
  5. pmc Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer
    Daniel Laheru
    Department of Medical Oncology, Skip Viragh Center for Pancreatic Cancer Research and Patient Care, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 4M09, Baltimore, MD 21231, USA
    Invest New Drugs 30:2391-9. 2012
  6. pmc Clinical development of Listeria monocytogenes-based immunotherapies
    Dung T Le
    The Sidney Kimmel Cancer Center and the Skip Viragh Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Semin Oncol 39:311-22. 2012
  7. ncbi request reprint Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances
    Dung T Le
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Natl Compr Canc Netw 11:766-72. 2013
  8. ncbi request reprint Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer
    Katherine Y Fan
    From the aDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Statistics, Stanford University, Palo Alto, California cDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California and dDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, eDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, fRussell H Morgan Department of Radiology and Radiological Sciences, gDivision of Endocrinology and Metabolism, Department of Internal Medicine, and hDepartment of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Natl Compr Canc Netw 12:50-7. 2014
  9. pmc Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective
    Dung T Le
    The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 72:3439-44. 2012
  10. pmc A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction
    Dung T Le
    The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 18:858-68. 2012

Collaborators

Detail Information

Publications12

  1. pmc Cellular vaccine approaches
    Dung T Le
    Department of Oncology, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans St, Bunting Blaustein Cancer Research Building, Room 407, Baltimore, MD 21231, USA
    Cancer J 16:304-10. 2010
    ....
  2. pmc CD8⁺ Foxp3⁺ tumor infiltrating lymphocytes accumulate in the context of an effective anti-tumor response
    Dung T Le
    The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Int J Cancer 129:636-47. 2011
    ..CD8(+) Foxp3(+) TILs mark the presence of tumor-rejecting antigen-specific T cells and their accumulation serves as a marker for an effective T cell response...
  3. pmc Evaluation of ipilimumab in combination with allogeneic pancreatic tumor cells transfected with a GM-CSF gene in previously treated pancreatic cancer
    Dung T Le
    The Sidney Kimmel Cancer Center, the Skip Viragh Center for Pancreatic Cancer, Research and Clinical Care, and the Sol Goldman Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    J Immunother 36:382-9. 2013
    ..014) and enhancement of the T-cell repertoire (P = 0.031). In conclusion, checkpoint blockade in combination with GVAX has the potential for clinical benefit and should be evaluated in a larger study...
  4. ncbi request reprint Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer
    Joseph M Herman
    Department of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Int J Radiat Oncol Biol Phys 86:678-85. 2013
    ..Gemcitabine-erlotinib therapy has demonstrated a survival benefit for patients with metastatic PDAC. Here we report the first phase 2 study of erlotinib in combination with adjuvant chemoradiation and chemotherapy for resected PDAC...
  5. pmc Integrated preclinical and clinical development of S-trans, trans-Farnesylthiosalicylic Acid (FTS, Salirasib) in pancreatic cancer
    Daniel Laheru
    Department of Medical Oncology, Skip Viragh Center for Pancreatic Cancer Research and Patient Care, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting Blaustein Cancer Research Building, Room 4M09, Baltimore, MD 21231, USA
    Invest New Drugs 30:2391-9. 2012
    ..This study evaluated the activity, safety, and toxicity of salirasib in preclinical models and patients with metastatic pancreatic adenocarcinoma (PDA)...
  6. pmc Clinical development of Listeria monocytogenes-based immunotherapies
    Dung T Le
    The Sidney Kimmel Cancer Center and the Skip Viragh Pancreatic Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Semin Oncol 39:311-22. 2012
    ....
  7. ncbi request reprint Next-generation cancer vaccine approaches: integrating lessons learned from current successes with promising biotechnologic advances
    Dung T Le
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA
    J Natl Compr Canc Netw 11:766-72. 2013
    ....
  8. ncbi request reprint Baseline hemoglobin-A1c impacts clinical outcomes in patients with pancreatic cancer
    Katherine Y Fan
    From the aDepartment of Radiation Oncology and Molecular Radiation Sciences, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland bDepartment of Statistics, Stanford University, Palo Alto, California cDepartment of Radiation Oncology, University of California San Francisco, San Francisco, California and dDepartment of Oncology, Sidney Kimmel Comprehensive Cancer Center, eDepartment of Pathology, The Sol Goldman Pancreatic Cancer Research Center, fRussell H Morgan Department of Radiology and Radiological Sciences, gDivision of Endocrinology and Metabolism, Department of Internal Medicine, and hDepartment of Surgery, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland
    J Natl Compr Canc Netw 12:50-7. 2014
    ..5% or greater influence OS of patients with PDA even when accounting for other known prognostic factors. HbA1c level at presentation is significantly higher in patients with PDA than patients with BPD and seems to affect survival. ..
  9. pmc Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective
    Dung T Le
    The Sidney Kimmel Cancer Center at Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Cancer Res 72:3439-44. 2012
    ..This review focuses on the use of cyclophosphamide in targeting Tregs to augment cancer vaccine approaches. However, these principles can also be applied to other immunotherapy strategies...
  10. pmc A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction
    Dung T Le
    The Sidney Kimmel Cancer Center, Johns Hopkins, Baltimore, Maryland 21231, USA
    Clin Cancer Res 18:858-68. 2012
    ..These two phase I studies test ANZ-100 and CRS-207 in subjects with liver metastases and mesothelin-expressing cancers, respectively...
  11. pmc A multicenter analysis of GTX chemotherapy in patients with locally advanced and metastatic pancreatic adenocarcinoma
    Ana De Jesus-Acosta
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, CRB I, Room 590, Baltimore, MD 21231, USA
    Cancer Chemother Pharmacol 69:415-24. 2012
    ..We were interested in determining the clinical benefit of another three-drug regimen of gemcitabine, docetaxel and capecitabine (GTX) in patients with advanced pancreatic adenocarcinoma...
  12. pmc Tyrosine 23 phosphorylation-dependent cell-surface localization of annexin A2 is required for invasion and metastases of pancreatic cancer
    Lei Zheng
    The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    PLoS ONE 6:e19390. 2011
    ..Thus, ANXA2 is part of a novel molecular pathway underlying PDA metastases and a new target for development of PDA therapeutics...